Skip to main content
Top
Published in: Cardiovascular Intervention and Therapeutics 2/2018

01-04-2018 | Original Article

Comparison of early-phase arterial repair following cobalt-chrome everolimus-eluting stent and slow-release zotarolimus-eluting stent: an angioscopic study

Authors: Takayuki Ishihara, Osamu Iida, Masashi Fujita, Masaharu Masuda, Shin Okamoto, Kiyonori Nanto, Takashi Kanda, Takuya Tsujimura, Akihiro Sunaga, Masaki Awata, Shinsuke Nanto, Masaaki Uematsu

Published in: Cardiovascular Intervention and Therapeutics | Issue 2/2018

Login to get access

Abstract

Whether arterial repair following implantation of drug-eluting stents (DES) of the second generation differs among stent types remains unknown. We examined 41 DES placed in 28 patients (age 72 ± 7 years, male 89%) presenting with stable angina pectoris due to de novo lesions in native coronary arteries. Coronary angioscopy was performed 4 ± 1 months after stent implantation. Patients were divided into two groups based on the DES types: 22 cobalt-chrome everolimus-eluting stents (CoCr-EES) in 13 patients and 19 slow-release zotarolimus-eluting stents (R-ZES) in 15 patients. Neointimal coverage (NIC) was graded as: grade 0, stent struts exposed; grade 1, struts bulging into the lumen, although covered; grade 2, struts embedded in the neointima, but translucent; grade 3, struts fully embedded and invisible. NIC was defined as heterogeneous when the NIC grade variation was ≥1. Presence of thrombus was also investigated. Distribution of dominant NIC grade (CoCr-EES: grade 0, 9%; grade 1, 77%; grade 2, 9%; grade 3, 5%; R-ZES: grade 0, 16%; grade 1: 47%; grade 2, 37%; grade 3, 0%, P = 0.38) and heterogeneity of NIC (P = 0.43) were similar between CoCr-EES and R-ZES groups. Existence of thrombus was not significantly different in CoCr-EES and R-ZES (18 versus 42%, P = 0.17). Arterial repair occurred without significant differences between CoCr-EES and R-ZES 4 months after implantation.
Literature
2.
go back to reference Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, et al. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. J Am Coll Cardiol Interv. 2014;7:471–81.CrossRef Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, et al. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. J Am Coll Cardiol Interv. 2014;7:471–81.CrossRef
3.
go back to reference Navarese EP, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ. 2013;347:f6530.CrossRefPubMedPubMedCentral Navarese EP, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ. 2013;347:f6530.CrossRefPubMedPubMedCentral
4.
go back to reference Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016;134:e123–55. doi:10.1161/CIR.0000000000000404.CrossRefPubMed Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016;134:e123–55. doi:10.​1161/​CIR.​0000000000000404​.CrossRefPubMed
5.
go back to reference Sakai S, Mizuno K, Yokoyama S, Tanabe J, Shinada T, Seimiya K, et al. Morphologic changes in infarct-related plaque after coronary stent placement: a serial angioscopy study. J Am Coll Cardiol. 2003;42:1558–65.CrossRefPubMed Sakai S, Mizuno K, Yokoyama S, Tanabe J, Shinada T, Seimiya K, et al. Morphologic changes in infarct-related plaque after coronary stent placement: a serial angioscopy study. J Am Coll Cardiol. 2003;42:1558–65.CrossRefPubMed
6.
go back to reference Takano M, Mizuno K, Yokoyama S, Seimiya K, Ishibashi F, Okamatsu K, et al. Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy. J Am Coll Cardiol. 2003;42:680–6.CrossRefPubMed Takano M, Mizuno K, Yokoyama S, Seimiya K, Ishibashi F, Okamatsu K, et al. Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy. J Am Coll Cardiol. 2003;42:680–6.CrossRefPubMed
7.
go back to reference Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47:2108–11.CrossRefPubMed Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47:2108–11.CrossRefPubMed
8.
go back to reference Awata M, Nanto S, Uematsu M, Morozumi T, Watanabe T, Onishi T, et al. Heterogeneous arterial healing in patients following paclitaxel-eluting stent implantation: comparison with sirolimus-eluting stents. J Am Coll Cardiol Interv. 2009;2:453–8.CrossRef Awata M, Nanto S, Uematsu M, Morozumi T, Watanabe T, Onishi T, et al. Heterogeneous arterial healing in patients following paclitaxel-eluting stent implantation: comparison with sirolimus-eluting stents. J Am Coll Cardiol Interv. 2009;2:453–8.CrossRef
9.
go back to reference Ishihara T, Awata M, Sera F, Fujita M, Watanabe T, Iida O, et al. Arterial repair 4 months after zotarolimus-eluting stent implantation observed on angioscopy. Circ J. 2013;77:1186–92.CrossRefPubMed Ishihara T, Awata M, Sera F, Fujita M, Watanabe T, Iida O, et al. Arterial repair 4 months after zotarolimus-eluting stent implantation observed on angioscopy. Circ J. 2013;77:1186–92.CrossRefPubMed
10.
go back to reference den Heijer P, Foley DP, Hillege HL, Lablanche JM, van Dijk RB, Franzen D, European Working Group on Coronary Angioscopy, et al. The ‘Ermenonville’ classification of observations at coronary angioscopy—evaluation of intra- and inter-observer agreement. European Working Group on Coronary Angioscopy. Eur Heart J. 1994;15:815–22.CrossRef den Heijer P, Foley DP, Hillege HL, Lablanche JM, van Dijk RB, Franzen D, European Working Group on Coronary Angioscopy, et al. The ‘Ermenonville’ classification of observations at coronary angioscopy—evaluation of intra- and inter-observer agreement. European Working Group on Coronary Angioscopy. Eur Heart J. 1994;15:815–22.CrossRef
11.
go back to reference Dai K, Matsuoka H, Kawakami H, Sato T, Watanabe K, Nakama Y, et al. Comparison of chronic angioscopic findings of bare metal stents, 1st-generation drug-eluting stents and 2nd-generation drug-eluting stents—Multicenter Study of Intra-Coronary Angioscopy After Stent (MICASA). Circ J. 2016;80:1916–21.CrossRefPubMed Dai K, Matsuoka H, Kawakami H, Sato T, Watanabe K, Nakama Y, et al. Comparison of chronic angioscopic findings of bare metal stents, 1st-generation drug-eluting stents and 2nd-generation drug-eluting stents—Multicenter Study of Intra-Coronary Angioscopy After Stent (MICASA). Circ J. 2016;80:1916–21.CrossRefPubMed
12.
go back to reference Nishimoto Y, Matsuo K, Ueda Y, Sugihara R, Hirata A, Murakami A, et al. Angioscopic comparison of resolute and endeavor zotarolimus-eluting stents. Circ J. 2016;80:650–6.CrossRefPubMed Nishimoto Y, Matsuo K, Ueda Y, Sugihara R, Hirata A, Murakami A, et al. Angioscopic comparison of resolute and endeavor zotarolimus-eluting stents. Circ J. 2016;80:650–6.CrossRefPubMed
13.
go back to reference Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T, Onishi T, et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation. 2007;116:910–6.CrossRefPubMed Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T, Onishi T, et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation. 2007;116:910–6.CrossRefPubMed
14.
go back to reference Haase J, Escaned J, van Swijndregt EM, Ozaki Y, Gronenschild E, Slager CJ, et al. Experimental validation of geometric and densitometric coronary measurements on the new generation Cardiovascular Angiography Analysis System (CAAS II). Cathet Cardiovasc Diagn. 1993;30:104–14.CrossRefPubMed Haase J, Escaned J, van Swijndregt EM, Ozaki Y, Gronenschild E, Slager CJ, et al. Experimental validation of geometric and densitometric coronary measurements on the new generation Cardiovascular Angiography Analysis System (CAAS II). Cathet Cardiovasc Diagn. 1993;30:104–14.CrossRefPubMed
15.
go back to reference Kim JS, Kim BK, Jang IK, Shin DH, Ko YG, Choi D, et al. ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). Am Heart J. 2012;163:601–7.CrossRefPubMed Kim JS, Kim BK, Jang IK, Shin DH, Ko YG, Choi D, et al. ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). Am Heart J. 2012;163:601–7.CrossRefPubMed
16.
go back to reference Kim S, Kim JS, Shin DH, Kim BK, Ko YG, Choi D, et al. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography. Am J Cardiol. 2013;111:1–5.CrossRefPubMed Kim S, Kim JS, Shin DH, Kim BK, Ko YG, Choi D, et al. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography. Am J Cardiol. 2013;111:1–5.CrossRefPubMed
17.
go back to reference Inoue T, Shinke T, Otake H, Nakagawa M, Hariki H, Osue T, et al. Neoatherosclerosis and mural thrombus detection after sirolimus-eluting stent implantation. Circ J. 2014;78:92–100.CrossRefPubMed Inoue T, Shinke T, Otake H, Nakagawa M, Hariki H, Osue T, et al. Neoatherosclerosis and mural thrombus detection after sirolimus-eluting stent implantation. Circ J. 2014;78:92–100.CrossRefPubMed
18.
go back to reference Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64:2086–97.CrossRefPubMed Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64:2086–97.CrossRefPubMed
19.
go back to reference Natsuaki M, Morimoto T, Yamamoto E, Shiomi H, Furukawa Y, Abe M, et al. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: shortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc Interv Ther. 2016;31:196–209.CrossRefPubMed Natsuaki M, Morimoto T, Yamamoto E, Shiomi H, Furukawa Y, Abe M, et al. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: shortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc Interv Ther. 2016;31:196–209.CrossRefPubMed
20.
go back to reference Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435–41.CrossRefPubMed Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435–41.CrossRefPubMed
21.
Metadata
Title
Comparison of early-phase arterial repair following cobalt-chrome everolimus-eluting stent and slow-release zotarolimus-eluting stent: an angioscopic study
Authors
Takayuki Ishihara
Osamu Iida
Masashi Fujita
Masaharu Masuda
Shin Okamoto
Kiyonori Nanto
Takashi Kanda
Takuya Tsujimura
Akihiro Sunaga
Masaki Awata
Shinsuke Nanto
Masaaki Uematsu
Publication date
01-04-2018
Publisher
Springer Japan
Published in
Cardiovascular Intervention and Therapeutics / Issue 2/2018
Print ISSN: 1868-4300
Electronic ISSN: 1868-4297
DOI
https://doi.org/10.1007/s12928-017-0465-x

Other articles of this Issue 2/2018

Cardiovascular Intervention and Therapeutics 2/2018 Go to the issue